{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:17:57Z","timestamp":1773922677251,"version":"3.50.1"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            EDP-420 (EP-013420, S-013420) is a first-in-class bicyclolide (bridged bicyclic macrolide) currently in clinical development for the treatment of respiratory tract infections. It has good preclinical pharmacokinetic properties across multiple species and potent in vitro and in vivo activity against respiratory tract infection pathogens, including\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            , atypical organisms (e.g.,\n            <jats:italic>Chlamydia pneumoniae, Mycoplasma pneumoniae<\/jats:italic>\n            , and\n            <jats:italic>Legionella pneumophila<\/jats:italic>\n            ), and multidrug-resistant streptococci. The safety, tolerability, and pharmacokinetics of an orally administered EDP-420 suspension in 40 healthy adult subjects were assessed in a randomized, double-blind, placebo-controlled, ascending single-dose study. Eligible subjects were sequentially randomized into one of five study groups (i.e., 100-, 200-, 400-, 800-, or 1,200-mg dosing groups) consisting of eight subjects (six active and two placebo) each. EDP-420 was well tolerated. There were no serious adverse events reported, nor were there any dose-limiting clinical or laboratory adverse events reported. EDP-420 was rapidly absorbed after a single oral dose. The mean plasma terminal half-life ranged from 15.6 to 20.1 h with low clearance. At the 400-mg dose, the area under the curve was 14.4 \u03bcg\u00b7h\/ml, which well exceeded the required area under the concentration-time curve to cover common respiratory tract infection pathogens based on preclinical pharmacokinetic\/pharmacodynamic modeling. The long half-life and high systemic exposure of EDP-420 support once-daily dosing and may allow for shorter treatment durations compared to other macrolide antibiotics. Based on its human pharmacokinetic profiles, taken together with its in vitro\/in vivo activity against common respiratory pathogens, EDP-420 warrants efficacy trials for the treatment of respiratory tract infections.\n          <\/jats:p>","DOI":"10.1128\/aac.01270-08","type":"journal-article","created":{"date-parts":[[2009,2,18]],"date-time":"2009-02-18T09:19:54Z","timestamp":1234948794000},"page":"1786-1792","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics of EDP-420 after Ascending Single Oral Doses in Healthy Adult Volunteers"],"prefix":"10.1128","volume":"53","author":[{"given":"Li-Juan","family":"Jiang","sequence":"first","affiliation":[{"name":"Enanta Pharmaceuticals, Inc., Watertown, Massachusetts 02472"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Wang","sequence":"additional","affiliation":[{"name":"Enanta Pharmaceuticals, Inc., Watertown, Massachusetts 02472"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yat Sun","family":"Or","sequence":"additional","affiliation":[{"name":"Enanta Pharmaceuticals, Inc., Watertown, Massachusetts 02472"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/513953"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332408"},{"key":"e_1_3_2_4_2","unstructured":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007"},{"key":"e_1_3_2_5_2","unstructured":"Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. 2005"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01303-06"},{"key":"e_1_3_2_7_2","unstructured":"Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. 2005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.11.2447"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/BF01975839","volume":"10","year":"1991","unstructured":"Coates, P., R. Daniel, A. C. Houston, J. H. Antrobus, and T. Taylor. 1991. An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers. Eur. J. Clin. Microbiol. Infect. Dis.10:850-852.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_10_2","unstructured":"Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. 2006"},{"key":"e_1_3_2_11_2","unstructured":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2147-2150.2001"},{"key":"e_1_3_2_13_2","unstructured":"Abstr. 17th Eur. Cong. Clin. Microbiol. Infect. Dis.\/25th Int. Cong. Chemother. 2007"},{"key":"e_1_3_2_14_2","unstructured":"Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. 2005"},{"key":"e_1_3_2_15_2","unstructured":"Abstr. 17th Eur. Cong. Clin. Microbiol. Infect. Dis.\/25th Int. Cong. Chemother. 2007"},{"key":"e_1_3_2_16_2","unstructured":"Abstr. 17th Eur. Cong. Clin. Microbiol. Infect. Dis. and 25th Int. Cong. Chemother. 2007"},{"key":"e_1_3_2_17_2","unstructured":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007"},{"key":"e_1_3_2_18_2","unstructured":"Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. 2005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/BF01975832","volume":"10","year":"1991","unstructured":"Lode, H. 1991. The pharmacokinetics of azithromycin and their clinical significance. Eur. J. Clin. Microbiol. Infect. Dis.10:807-812.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_20_2","unstructured":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007"},{"key":"e_1_3_2_21_2","unstructured":"Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. 2004"},{"key":"e_1_3_2_22_2","unstructured":"Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. 2005"},{"key":"e_1_3_2_23_2","unstructured":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.170-175.2001"},{"key":"e_1_3_2_25_2","unstructured":"Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. 2006"},{"key":"e_1_3_2_26_2","unstructured":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007"},{"key":"e_1_3_2_27_2","unstructured":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007"},{"key":"e_1_3_2_28_2","unstructured":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007"},{"key":"e_1_3_2_29_2","unstructured":"Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. 2003"},{"key":"e_1_3_2_30_2","unstructured":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/jac\/dkm505","volume":"61","year":"2008","unstructured":"Stucki, A., P. Gerber, F. Acosta, M. Cottagnoud, P. Cottagnoud, L. Jiang, P. Nguyen, D. Wachtel, G. Wang, and L. T. Phan. 2008. Effects of EDP-420 on penicillin-resistant and quinolone- and penicillin-resistant pneumococci in the rabbit meningitis model. J. Antimicrob. Chemother.61:665-669.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_32_2","unstructured":"Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. 2005"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/21.suppl_D.45","volume":"21","year":"1988","unstructured":"Tuominen, R. K., P. T. Mannisto, P. Pohto, A. Solkinen, and A. Vuorela. 1988. Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state. J. Antimicrob. Chemother.21(Suppl. D):45-55.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1021\/ol048336r","volume":"6","year":"2004","unstructured":"Wang, G., D. Niu, Y. L. Qiu, L. T. Phan, Z. Chen, A. Polemeropoulos, and Y. S. Or. 2004. Synthesis of novel 6,11-O-bridged bicyclic ketolides via a palladium-catalyzed bis-allylation. Org. Lett.6:4455-4458.","journal-title":"Org. Lett."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11908-005-0031-z","volume":"7","year":"2005","unstructured":"Wierzbowski, A. K., D. J. Hoban, T. Hisanaga, M. Decorby, and G. G. Zhanel. 2005. The use of macrolides in treatment of upper respiratory tract infections. Curr. Infect. Dis. Rep.7:175-184.","journal-title":"Curr. Infect. Dis. Rep."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm273"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.281-288.2005"},{"key":"e_1_3_2_38_2","unstructured":"46th Intersci. Conf. Antimicrob. Agents Chemother. 2006"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01538-07"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01270-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01270-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:20:59Z","timestamp":1645474859000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01270-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1128\/AAC.01270-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.01270-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"2008-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}